Cresskill, NJ – According to filings with the U.S. Securities and Exchange Commission, Vascular Therapies is raising $25,213,472.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, John Mcdermott played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vascular Therapies
Vascular Therapies, Inc., a privately-held late-stage biopharmaceutical company, is developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery. The goal of this patent protected, innovative therapeutic approach is to address the problem of hemodialysis vascular access failure with the intent of bridging an important unmet medical need in patients with kidney failure. The product is regulated as a drug in the US, EU and Japan and Sirolimus has Orphan Drug status for the dialysis vascular access indications in the U.S. and E.U.

To learn more about Vascular Therapies, visit http://www.vasculartx.com/

Contact:
John Mcdermott, Chief Executive Officer
201-266-8310
jmcdermott@vasculartx.com
https://www.linkedin.com/in/jdmcdermott/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved